Recordati Industria Chimica e Farmaceutica S.p.A. RCDTF · Stock Open Recordati Industria Chimica e Farmaceutica S.p.A. in new tab
Recordati Industria Chimica e Farmaceutica S.p.A. Analysis (RCDTF)
Is Recordati Industria Chimica e Farmaceutica S.p.A. a good investment? Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) is currently trading at 60.00 USD.
In terms of valuation, the stock trades at a P/E ratio of 22.81. This valuation is generally in line with the broader market.
Earnings Schedule: Recordati Industria Chimica e Farmaceutica S.p.A. is expected to release its next earnings report on July 28, 2026.
For income investors, Recordati Industria Chimica e Farmaceutica S.p.A. pays a dividend yield of 2.64%. With a payout ratio of 57%, the dividend appears sustainable.
Investor FAQ
Does Recordati Industria Chimica e Farmaceutica S.p.A. pay a dividend?
Yes, it pays an annual dividend of 1.34 USD (2.64% yield).
What asset class is Recordati Industria Chimica e Farmaceutica S.p.A.?
Recordati Industria Chimica e Farmaceutica S.p.A. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 28, 2026. The company currently has a trailing EPS of 2.63.
Company Profile
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing's syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
| Year | Total Dividends |
|---|---|
| ▸2027 |
0.87 USD
|
| May 26, 2027 (estimated) | 0.8672 |
| ▸2026 |
1.56 USD
|
| Nov. 25, 2026 (estimated) | 0.7401 |
| May 20, 2026 | 0.8237 |
| ▸2025 |
1.48 USD
|
| Nov. 26, 2025 | 0.7257 |
| May 21, 2025 | 0.7540 |
| ▸2024 |
1.32 USD
|
| Nov. 20, 2024 | 0.6352 |
| May 22, 2024 | 0.6842 |
| ▸2023 |
1.27 USD
|
| Nov. 22, 2023 | 0.6235 |
| May 24, 2023 | 0.6483 |
| ▸2022 |
1.17 USD
|
| Nov. 23, 2022 | 0.5632 |
| May 25, 2022 | 0.6082 |
| ▸2021 |
1.27 USD
|
| Nov. 24, 2021 | 0.5961 |
| May 26, 2021 | 0.6715 |
| ▸2020 |
1.16 USD
|
| Nov. 25, 2020 | 0.5908 |
| May 20, 2020 | 0.5670 |
| ▸2019 |
1.06 USD
|
| Nov. 20, 2019 | 0.5319 |
| April 25, 2019 | 0.5270 |
| ▸2018 |
1.04 USD
|
| Nov. 21, 2018 | 0.5154 |
| April 25, 2018 | 0.5252 |
| ▸2017 |
0.87 USD
|
| Nov. 22, 2017 | 0.4934 |
| April 26, 2017 | 0.3797 |
| ▸2016 |
0.71 USD
|
| Nov. 23, 2016 | 0.3718 |
| April 20, 2016 | 0.3396 |
| ▸2015 |
0.58 USD
|
| Nov. 11, 2015 | 0.3224 |
| April 22, 2015 | 0.2583 |
| ▸2014 |
0.48 USD
|
| Nov. 19, 2014 | 0.3239 |
| May 2, 2014 | 0.1523 |
| ▸2013 |
0.43 USD
|
| Nov. 21, 2013 | 0.2976 |
| April 25, 2013 | 0.1305 |
| ▸2012 |
0.39 USD
|
| Nov. 22, 2012 | 0.2563 |
| April 26, 2012 | 0.1313 |
| ▸2011 |
0.66 USD
|
| Nov. 24, 2011 | 0.2693 |
| April 21, 2011 | 0.3908 |
| ▸2010 |
0.37 USD
|
| April 29, 2010 | 0.3667 |
| ▸2009 |
0.32 USD
|
| April 23, 2009 | 0.3230 |
| ▸2008 |
0.34 USD
|
| April 24, 2008 | 0.3421 |
| ▸2007 |
0.25 USD
|
| April 27, 2007 | 0.2513 |
| ▸2006 |
0.17 USD
|
| April 27, 2006 | 0.1702 |
| ▸2005 |
0.14 USD
|
| April 28, 2005 | 0.1430 |
| ▸2004 |
0.45 USD
|
| April 22, 2004 | 0.4507 |
| ▸2003 |
0.41 USD
|
| April 25, 2003 | 0.4078 |
| ▸2002 |
0.22 USD
|
| April 25, 2002 | 0.2226 |
| ▸2001 |
0.14 USD
|
| May 10, 2001 | 0.1386 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Recordati Industria Chimica e Farmaceutica S.p.A. | May 20, 2026 | Paid | 0.8237 USD |
| Recordati Industria Chimica e Farmaceutica S.p.A. | Nov 26, 2025 | Paid | 0.72565 USD |
Community Discussion